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Purpose: Methotrexate (MTX) treatment is associated with lower blood pressure (BP) and 
arterial stiffness in rheumatoid arthritis (RA). We investigated associations between single-
nucleotide polymorphism (SNP) of the ATP-binding cassette efflux transporter gene ABCG2 
(rs2231142), BP, and arterial stiffness in RA patients treated with MTX.
Patients and methods: Clinical and 24-hour peripheral and central BP, arterial wave reflec-
tion (Augmentation Index, AIx), arterial stiffness (Pulse Wave Velocity, PWV), and intracellular 
MTX polyglutamate (MTXPGs) concentrations were assessed in 56 RA patients on stable treat-
ment with MTX using a repeated cross-sectional study design with measurements at baseline 
and after 8 months.
Results: Majority of the RA patients were homozygotes for the normal allele (CC, n=46) whereas 
10 were rs2231142 heterozygotes (AC, n=10). MTXPGs concentrations were non-significantly 
higher in AC when compared to CC (144.3 vs 116.3 nmol/L packed RBCs, P=0.10). At baseline, 
the AC group had significantly lower age-adjusted clinical systolic BP (SBP) (P=0.01), 24-hour 
peripheral SBP (P=0.003), and central SBP (P=0.02) when compared to the CC group. How-
ever, AIx and PWV values were not significantly different between the two groups. When data 
from both visits were combined in a single analysis, and additionally adjusted for visit, gender, 
body mass index, and Disease Activity Score 28, the trend in SBP differences between-groups 
persisted but was no longer significant.
Conclusion: Future studies are required to test the hypothesis that this genetic polymorphism 
is associated with lower BP, arterial stiffness, and possibly, cardiovascular risk, in RA patients 
treated with MTX.
Keywords: methotrexate, disease-modifying antirheumatic drugs, blood pressure, augmentation 
index, rheumatoid arthritis, pulse wave velocity, single-nucleotide polymorphisms, ATP-binding 
cassette transporters, ABCG2
Introduction
The multidrug resistant ATP-binding cassette efflux transporter ABCG2, encoded by 
the ABCG2 gene in chromosome 4q22, is located in the membrane of various cells, 
including hepatocytes, renal cells, and enterocytes.1 Its main function is to reduce 
excessive exposure to toxins and drugs, including disease modifying anti-rheumatic 
drugs (DMARDs) such as methotrexate (MTX).2 ABCG2 transports not only MTX, 
but also its polyglutamate forms, specifically polyglutamate 2 and 3, and plays a key 
role in the absence of other transporters, such as ABCC2.3,4 The most common ABCG2 
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single nucleotide polymorphism (SNP) is rs2231142, where 
the C nucleotide is substituted for A at position number 421 
(C421A), resulting in loss of ABCG2 function.4 Although 
studies have claimed that rs2231142 SNP does not influence 
the clinical response to MTX,5 a recent study showed that 
ABCG2 SNP influenced not only MTX treatment response 
but also its discontinuation.6 However, there is no conclusive 
evidence until now regarding the relationship between this 
SNP and MTX response rate in patients with rheumatoid 
arthritis (RA). We have recently reported that treatment 
with MTX is associated with lower blood pressure (BP) and 
pulse-wave velocity (PWV), a marker of arterial stiffness, 
in this group.7,8 These associations might explain, at least 
in part, the lower incidence of cardiovascular (CV) events 
in RA patients treated with MTX when compared to other 
DMARDs in epidemiological studies.9 Here, we seek to 
investigate the associations between the ABCG2 C421A 
SNP on red blood cell MTX polyglutamate concentrations 
(MTXPGs), BP, and arterial stiffness in RA patients treated 
with MTX in our RA cohort.
Methods
Patient recruitment and assessment have been described in 
detail elsewhere.7,8 Briefly, we studied a consecutive series 
of adult RA patients treated with MTX for at least 8 weeks. 
The study (registered in the Australian New Zealand  Clinical 
 Trials Registry, ACTRN12616001366448) was approved 
by the Southern Adelaide Clinical Human Research Ethics 
Committee (Ethics Approval Number: 76.14). Each partici-
pant gave an informed written consent before enrolling in 
the study.
MTXPGs, clinical and 24-hour peripheral and central BP, 
and markers of arterial stiffness (PWV and augmentation 
index, AIx) were assessed in two separate visits, at baseline 
and after 8-months.7,8 Genomic DNA was extracted from 
peripheral blood mononuclear cells. The concentration and 
purity of the samples was determined using a Nanodrop 
(Thermo Fisher Scientific, Waltham, MA, USA). The DNA 
was plated into a 96-well master plate at 5 ng/µL. The ABCG2 
421C-A SNP (rs2231142) was determined by TaqMan® 
SNP genotyping assays using an ABI 7500 Fast Real-Time 
PCR system (Applied Biosystems, Carlsbad, CA, USA). 
After genotyping, and due to the relatively low frequency 
of the A allele, participants were classified based on their 
ABCG2 C421A status as: 1) loss of function, as determined 
by carriage of at least one copy of the A allele (ie., AA 
or AC genotype); or 2) normal function, or homozygote 
for the C allele (ie., CC genotype). Both the AC and CC 
groups were identified from within the same MTX-treated 
RA patient cohort, making the two genotype groups more 
likely to be comparable in terms of clinical and demographic 
characteristics.
Clinical peripheral SBP was the primary study end-point. 
Clinical peripheral diastolic BP (DBP), central BP, AIx, 
24-hour peripheral and central BP, and PWV were secondary 
end-points. Based on our previous studies,7 a sample size 
of 56 RA patients treated with MTX provided 80% power 
(alpha=0.05) to detect a difference of 10 mmHg in SBP 
between the MTX and non-MTX groups. Variables were 
tested for normal distribution using the Kolmogorov-Smirnov 
test. Results are expressed as means ± SD, medians and 
interquartile ranges, or frequencies, as appropriate. Given the 
significant difference in age between the two genotype groups 
in this study, as well as the known impact of age on BP,10 
AIx,11 and PWV,12 we calculated age-adjusted values prior to 
each comparison, and reported the age-adjusted means. We 
then combined the data from the baseline and 8-month visits 
and performed a between-genotype group comparison using 
a mixed effects model with adjustment for visit, age, gender, 
body mass index (BMI), and disease activity, as measured 
by the 28-joint Disease Activity Score (DAS28), which were 
included as fixed effects. The subject ID was included as a 
random intercept. Analyses were performed using Stata® 
software version 14.2 (StataCorp, TX, USA).
Results
The majority of RA patients carried the CC genotype (n=46) 
whereas the remaining 10 carried the AC genotype. The CC 
group was significantly older than the AC group (52±18.7 
vs 63±11 years, P=0.01; Table 1). The AC group had sig-
nificantly lower age-adjusted peripheral and central SBP, 
and a trend towards lower peripheral and central DBP, when 
compared to the CC group (Table 1). The mean 24-hour-
peripheral and central SBP values were also significantly 
lower in the AC group (Table 1). However, there were no 
significant between-group differences in AIx or PWV. After 
adjusting for MTX dose and duration, intracellular MTXPG 
concentrations were higher, albeit not significantly, in the AC 
group when compared to the CC group (Table 1). There was, 
however, a moderate positive correlation between clinical 
SBP and the level of MTXPGs in CC genotypes of ABCG2 
SNP (Figure 1).
When data from both visits were combined in a mixed 
effects model with adjustment for age, gender, BMI, DAS28, 
and visit, there were no significant between-group differences 
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aBcg2 polymorphism and blood pressure in ra
Discussion
This repeated cross-sectional study reported a significantly 
lower SBP, and a trend towards higher concentrations of 
MTXPGs, in RA patients with loss of function ABCG2 C421A 
genotypes when compared to patients who were homozygote 
for the normal allele. Although no longer  significant during 
Table 1 Baseline characteristics of subjects according to cc and ac genotyping of ABCG2 snP
CC genotype (n=46) AC genotype (n=10) P-value
age, years (mean ± sD) 63±11 52±18.7 0.01b
Females, n (%) 32 (69.6) 7 (70.0) 0.98
hypertension treatment, n (%) 15 (32.6) 1 (10.0) 0.15
BMi (kg/m2) 27.4±0.62 25.7±1.4 0.27
MTX dose (mg/week) 14.5±0.56 14±1.2 0.72
aMTXPgs (nmol/l packed rBcs) 116.3±7 144.3±15.3 0.10
crP (mg/l) 7±1.4 3.9±3.2 0.40
Das28 score 2.8±1.1 2.6±0.2 0.55
stanford haQ score 0.69±0.08 0.89±0.18 0.33
clinical peripheral sBP (mmhg) 127.2±1.5 117±3.5 0.01b
clinical peripheral DBP (mmhg) 74.1±1.1 69±2.5 0.07b
clinical central sBP (mmhg) 117.9±1.4 107±3.2 0.003c
clinical central DBP (mmhg) 76±1.1 70.8±2.5 0.06
24-hour peripheral sBP (mmhg) 119.8±1.9 109.2±4 0.02b
24-hour peripheral DBP (mmhg) 70±1.2 65.7±2.5 0.13
24-hour central sBP (mmhg) 116.4±1.4 108.9±3 0.02b
24-hour central DBP (mmhg) 76±0.90 73±1.9 0.18
aix (%) 30.4±1.1 25.7±2.4 0.07b
aix @ 75bpm (%) 28.1±0.90 26.03±2 0.36
24-hour aix @ 75bpm (%) 29±0.75 26.6±1.6 0.19
24-hour PWV (m/second) 9.01±0.09 9.04±0.20 0.91
Notes: all group means, except for age, are age-adjusted. aMeans are adjusted for MTX dose and duration. bP-value≤0.05. cP-value≤0.01. Data presented as mean ± standard 
deviation unless otherwise indicated.
Abbreviations: rBcs, red blood cells; BMi, body mass index; MTX, Methotrexate; MTXPgs, MTX polyglutamates; sBP, systolic blood pressure; DBP, diastolic blood 
pressure; aix, augmentation index; PWV, pulse wave velocity; crP, c-reactive protein.
Table 2 adjusted mean (95% ci) differences in BP, aix, PWV, and concentrations of MTXPgs between cc (n=46) and ac (n=10) 
polymorphisms of the MTX ABCG2 snP using combined data from baseline and 8 months
Model 1 Model 2 Model 3
b (95% CI) P-value b (95% CI) P-value b (95% CI) P-value
clinic peripheral sBP (mmhg) 6.2 (−3. 2, 15.5) 0.19 5.7 (−3.7, 15.1) 0.23 5.8 (−3.7, 15.4) 0.23
clinic peripheral DBP (mmhg) 1.9 (−4.4, 8.4) 0.55 1.7 (−4.7, 8.05) 0.61 1.4 (−5.03, 7.7) 0.68
clinic central sBP (mmhg) 7.3 (−1.7, 16.2) 0.11 7.0 (−2.0, 16.0) 0.13 7.02 (−2.1, 16.1) 0.13
clinic central DBP (mmhg) 2.7 (−3.7, 9.0) 0.41 2.3 (−4.0, 8.7) 0.47 1.9 (−4.4, 8.2) 0.56
aix @75 (%) −1.1 (−6.5, 4.2) 0.68 −0.92 (−6.3, 4.4) 0.74 −0.81 (−6.2, 4.6) 0.77
24-hour peripheral sBP (mmhg) 7.6 (−1.9, 17) 0.12 7.1 (−2.3, 16.4) 0.14 7.2 (−2.2, 16.6) 0.13
24-hour peripheral DBP (mmhg) 3.9 (−1.3, 9.1) 0.14 3.5 (−1.6, 8.7) 0.18 3.4 (−1.8, 8.6) 0.20
24-hour central sBP (mmhg) 4 (−2.9, 11.0) 0.26 3.1 (−3.7, 9.8) 0.37 3.4 (−3.3, 10.0) 0.32
24-hour central DBP (mmhg) 1.8 (−2.2, 6.0) 0.38 1.4 (−2.7, 5.4) 0.52 1.6 (−2.5, 5.6) 0.45
24-hour aix @75 (%) 1.3 (−2.5, 5.2) 0.50 1.3 (−2.5, 5.1) 0.50 1.6 (−2.2, 5.4) 0.42
24-hour PWV (m/second) −0.04 (−0.74, 0.66) 0.97 −0.1 (−0.76, 0.63) 0.85 −0.1 (−76, 0.65) 0.89
MTXPgs (nmol/l) 26.2 (−12.1, 64.5) 0.18 27.7 (−10.6, 65.9) 0.16 27.9 (−11.2, 67.0) 0.16
Notes: Model 1 = adjusted for age and visit; Model 2 = adjusted for age, visit, gender, and BMi; Model 3 = adjusted for age, visit, gender, BMi, and Das28. 
Abbreviations: BMi, body mass index; MTX, Methotrexate; MTXPgs, MTX polyglutamates; BP, blood pressure; sBP, systolic BP; DBP, diastolic BP; aix, augmentation 
index; PWV, pulse wave velocity; Das28, Disease activity score.
repeated assessment, the trend in between-group differences in 
SBP and DBP was maintained. We cannot rule out the possi-
bility that the study was underpowered to detect these smaller, 
although clinically important, average differences observed in 
the repeated analysis. A larger group of AC genotype patients 
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A few studies have failed to show that ABCG2 SNPs influ-
ence the clinical response to MTX.5,13 However, a recent study 
showed that ABCG2 SNPs are associated with MTX response 
in RA patients.6 Moreover, another study showed that A 
homozygotes have a reduced function of the ABCG2 trans-
porter (ie., reduced efflux capability of MTX).14 This results 
in greater MTX accumulation and better MTX response.15 
Furthermore, RA carriers of the AC genotype show bet-
ter disease activity.16 Although this was attributed to the 
DMARD sulphasalazine, 94% of the RA cohort was treated 
with MTX. In agreement with the latter studies, this study 
found that the mutant allele of ABCG2 (AC) is associated 
with higher RBC accumulation of MTXPGs. The AC allele 
is associated with reduced function of the MTX transporter, 
hence greater MTXPG accumulation. Our preliminary results 
suggest that a higher concentration of MTXPGs, albeit not 
significant, might be associated with the reported differences 
in SBP between the AC and the CC groups. As suggested in 
our previous studies, MTXPGs inhibit aminoimidazole car-
boxamide ribonucleotide transformylase.17 This leads to the 
accumulation of the substrate aminoimidazole carboxamide 
ribonucleotide and its metabolites which, in turn, inhibit 
adenosine deaminase and adenosine monophosphate deami-
nase.17 The accumulation of adenosine, with consequent BP 
lowering effects through peripheral and central mechanisms, 
might account for the reported differences in BP.18 Adenosine 
is known to cause vasodilation, either directly or through 
NO.19 Adenosine acts on the vascular endothelium via its 
receptors A1 and A2A and stimulates the release of PG, 
which enhances the release of nitric oxide (NO). Concur-
rently, adenosine acts centrally on the brain nucleus tractus, 
where adenosine activates endothelial NO synthase through 
A2A receptors. As a result, the level of NO is increased and 
thus, adenosine has a key role in modulating BP and arterial 
functions (Figure 2). The main strength of our study is the 
comprehensive repeated assessment of, clinical and over 
24-hours, peripheral and central BP and markers of arterial 
stiffness. The limitations of our study include the lack of 
adenosine assessment and the possibility that the study might 
be underpowered to identify the somewhat smaller average 
differences in the repeated analysis. Due to inter-individual 
variability, genetic polymorphisms might provide essential 
information for a personalized approach to initiate the dose 
of MTX and subsequent monitoring. This MTX personalized 
approach could then be used to examine BP and arterial func-
tion effects of MTX on other high-risk patients with diseases 
other than RA—for example, designing randomized control 
trials for high-risk cardiac patients using MTX. Moreover, 
Figure 1 association between clinical peripheral sBP and MTXPgs polyglutamate concentrations in MTX ABCG2 genotypes.
Abbreviations: clinical sBP, clinical peripheral systolic blood pressure; MTXPgs, methotrexate polyglutamates.
0.00
Spearman’s rho =0.13 (p=0.73) Spearman’s rho =0.14 (p=0.37)
Scatterplot of the association
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aBcg2 polymorphism and blood pressure in ra
Figure 2 Potential mechanisms explaining the effects of MTX on BP and arterial function in ra.
Abbreviations: MTX, methotrexate; FPgs, Folylpolyglutamate synthetase enzyme; aTic, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; nO, nitric 
oxide; enOs, endothelial nO synthase; Pg, prostaglandins; cgMP, cyclic guanosine-3′, 5-monophosphate; gTP, guanosine-5′-triphosphate; BP, blood pressure; PWV, pulse 
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this genetic polymorphism could provide vital information 
in the field of molecular biology and genetic engineering. In 
particular, changing the sequence of the DNA intentionally is 
a known technique for introducing a mutation in a particular 
gene; it is also called site-specific mutagenesis. Researchers 
could use this finding in constructing novel MTX analogues 
that are characterized by combined anti-inflammatory and 
BP/arterial function effects. The CV-protective effects of 
MTX have a pharmacological attraction. MTX could be 
reused for managing CV risk in not only RA patients but 
also in the general population. It might provide useful infor-
mation about the drug genetic variations that might assist 
physicians in personalizing the dose for high-risk patients. 
In conclusion, our study provides the first evidence of an 
association between genetic polymorphisms of MTX, and 
BP in RA patients. Further randomized-controlled studies are 
warranted to confirm these findings, and to establish whether 
these effects account for the reduced CV risk reported with 
MTX treatment.
Acknowledgment
Special thanks for the support by the College of Medicine 
Research Center, Deanship of Scientific Research, King Saud 
University Riyadh, Saudi Arabia.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the 
ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 
2003;55(1):3–29.
 2. van der Heijden JW, Oerlemans R, Tak PP, et al. Involvement of breast 
cancer resistance protein expression on rheumatoid arthritis synovial 
tissue macrophages in resistance to methotrexate and leflunomide. 
Arthritis Rheum. 2009;60(3):669–677.
 3. Vlaming ML, Pala Z, van Esch A, et al. Functionally overlapping roles 
of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrex-
ate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin 
Cancer Res. 2009;15(9):3084–3093.
 4. Volk EL, Schneider E. Wild-type breast cancer resistance protein 
(BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer 
Res. 2003;63(17):5538–5543.
 5. Kato T, Hamada A, Mori S, Saito H. Genetic polymorphisms in meta-
bolic and cellular transport pathway of methotrexate impact clinical 
outcome of methotrexate monotherapy in Japanese patients with rheu-
matoid arthritis. Drug Metab Pharmacokinet. 2012;27(2):192–199.
 6. Jenko B, Lusa L, Tomsic M, Praprotnik S, Dolzan V. Clinical-pharma-
cogenetic predictive models for MTX discontinuation due to adverse 
events in rheumatoid arthritis. Pharmacogenomics J. 2017;17(5): 
412–418.
 7. Mangoni AA, Baghdadi LR, Shanahan EM, et al. Methotrexate, blood 
pressure and markers of arterial function in patients with rheumatoid 
arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis. 
2017;9(9):213–229.
 8. Woodman RJ, Baghdadi LR, Shanahan ME, Mangoni AA. The Temporal 
Relationship between Arterial Stiffening and Blood Pressure Is Modi-
fied by Methotrexate Treatment in Patients with Rheumatoid Arthritis. 
Front Physiol. 2017;8:593.
 9. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review 
and meta-analysis of methotrexate use and risk of cardiovascular disease. 
Am J Cardiol. 2011;108(9):1362–1370.
 10. Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E. The 
association between aortic augmentation index and cardiovascular 
risk factors in a large unselected population. J Hum Hypertens. 
2012;26(8):476–484.
 11. Lee HY, Oh BH. Aging and arterial stiffness. Circ J. 2010;74(11): 
2257–2262.
 12. Alghatrif M, Strait JB, Morrell CH, et al. Longitudinal trajectories of 
arterial stiffness and the role of blood pressure: the Baltimore Longi-
tudinal Study of Aging. Hypertension. 2013;62(5):934–941.
 13. Stamp LK, Chapman PT, O’Donnell JL, et al. Polymorphisms within 
the folate pathway predict folate concentrations but are not associated 
with disease activity in rheumatoid arthritis patients on methotrexate. 
Pharmacogenet Genomics. 2010;20(6):367–376.
 14. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate 
with common polymorphisms in reduced folate carrier, aminoimidazole 
carboxamide ribonucleotide transformylase, and thymidylate synthase 
are associated with methotrexate effects in rheumatoid arthritis. Arthritis 
Rheum. 2004;50(9):2766–2774.
 15. Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull 
Hosp Jt Dis. 2013;71(Suppl 1):S5–8.
 16. Wiese MD, Alotaibi N, O’Doherty C, et al. Pharmacogenomics of 
NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine 
containing DMARD regimens in early rheumatoid arthritis. Pharma-
cogenomics J. 2014;14(4):350–355.
 17. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-
4-carboxamide ribotide transformylase, adenosine deaminase and 
5’-adenylate deaminase by polyglutamates of methotrexate and oxidized 
folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. 
Biochem J. 1986;236(1):193–200.
 18. Koupenova M, Johnston-Cox H, Ravid K. Regulation of atherosclerosis 
and associated risk factors by adenosine and adenosine receptors. Curr 
Atheroscler Rep. 2012;14(5):460–468.
 19. Li J, Fenton RA, Wheeler HB, et al. Adenosine A2a receptors 










































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
